Gilberto Pires da Rosa

Deixai-me estar.

[The Journal of Rheumatology @jrheum]

Images in Rheumatology

Pyoderma Gangrenosum-Associated Autoinflammatory Syndrome With Skin Abscesses: Successful Treatment With Anti-Interleukin 1 Therapy
@gpiresrosa @UPorto

📖 https://t.co/9J5VN0h31x

#PGAAIS #SkinAbscesses

[Neil Stone @DrNeilStone]

This "ivermectin treats absolutely everything" cult really is the dumbest thing I have encountered in my medical career. So far.

[Público @Publico]

O professor é um trabalhador por conta de outrem: o encarregado de educação https://t.co/w4OpSP7u5A

[Gilberto Pires da Rosa @gpiresrosa]

@gerardespinosa5 @pons_francesca Um médico com a docência no sangue, um mestre do percurso de muitos colegas! Mas há um erro no diapositivo, fala de nascimento a 1967, deve ser 77 ou 87, não? 😏 Muitos parabéns!

[A enfermeira imperfeita @enfermeira_a]

É bem capaz de ser a melhor cantora mexicana da actualidade. Gravou esta música num lar, com os velhos. E com velhos na guitarra, na voz e no videoclip, diz muito mais do que eu seria alguma vez capaz de escrever. https://t.co/QgZtwCpcyb

[Autoinmunes-Clínic @MAS_Clinic]

Check out our latest work on #APS
Longitudinal change of aGAPSS predicts the risk of recurrent thrombosis in #APS patients by @gatocobotas @hospitalclinic #antiphospholipid
https://t.co/49baFUzzra

[Giuseppe Barilaro @giubarilaro]

Longitudinal is better than transversal! Multiple is better than one time! Check out our brand new article on aGAPSS as predictor of clinical recurrence in APS.
https://t.co/ZRNPK4DagP @gerardespinosa5 @CerveraRicard @gpiresrosa @_alex_esteves_ @olgatgn

[APS Support UK @APSsupportUK]

This systematic review by @gpiresrosa, @NatxRP, @CerveraRicard, and @gerardespinosa5 compares ‘non-criteria’#AntiphospholipidSyndrome with 'definite' #APS: https://t.co/FDgB0X75Ug

[Frontiers - Immunology @FrontImmunol]

New Research: Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review: Objectives

Patients with laboratory or clinical manifestations suggestive of antiphospholipid syndrome (APS) but… https://t.co/ONXSd2mBY9 #immunology

[Gilberto Pires da Rosa @gpiresrosa]

Our systematic review of studies comparing non-criteria and definite #antiphospholipidsyndrome,hinting at an absence of marked differences in most evaluated variables,emphasizing the value of a more active follow-up of these patients.@FrontImmunol @gerardespinosa5 @CerveraRicard

[Autoinmunes-Clínic @MAS_Clinic]

Deciphering #antiphospholipidsyndrome by @gpiresrosa @NatxRP @CerveraRicard @gerardespinosa5
@FrontiersIn @hospitalclinic
https://t.co/OepyA1AEb8
@afosfolipido @APSFA @APSsupportUK
#APS
https://t.co/SIih266MpF

[Cristina Macía @reumacia]

Resumen preliminar de la guía 2022 ACR 🇺🇸 de vacunación en pacientes con enfermedades reumáticas e inmunosupresores 💉 💊 https://t.co/7vG4MMuGIk Via @mariaj_morenom

[Gilberto Pires da Rosa @gpiresrosa]

@Mariana78268891 @NOS_Alive Mais 2 aqui!

[Gilberto Pires da Rosa @gpiresrosa]

@nunottav Que álbum!

[Gilberto Pires da Rosa @gpiresrosa]

Our new paper on non-criteria #APS: patients with laboratory criteria and only nc-manifestations display mostly hematological involvement and less severe nc-manifs than definite APS. Some may progress to SLE.@MAS_Clinic @gerardespinosa5 @CerveraRicard https://t.co/cYFaHeApGx

[Gilberto Pires da Rosa @gpiresrosa]

@BuchaMyTugao Bucha!

[Mike Putman @EBRheum]

Editorial published today in Rheumatology about how to move beyond "1mg/kg then taper" regimens

We discuss recent trials in AAV and SLE. Take a look!

[45 Graus @45graus]

Um tema simultaneamente interessante e muito relevante, para o qual dificilmente poderia pedir melhor convidado: Nuno Loureiro é professor catedrático no MIT, com especialidade em física dos plasmas: aplicações à fusão nuclear e astrofísica. Não https://t.co/Xjo2wsuJEi

[Mike Putman @EBRheum]

Great talk @TerrierBen, pooled MAINRTISAN data

1. RTX > AZA
2. Fixed > Tailored --> w/longer fu, higher flares w/tailored
3. 18mo RTX ~ 36mo RTX... interesting

Strong presentation & fitting conclusion to a highly influential series of trials, kudos to FVSG! #vasculitis22